Many novel types of asthma therapeutic procedures have been investigated in the past decade. A vast amount of work in the 5-LO inhibitor and LT1-receptor antagonist area has resulted in a various of compounds being identified for clinical trails, and several compounds are used in the clinic. The impact of the LT1-receptor antagonist and 5-LO inhibitors on alergy therapy will be significant, if these compounds have an antiinflammatory effect within their mechanism. The area with possibly the most promise is selective inhibitors of phosphodiesterase enzymes (PDEs). Selective inhibitors of three isoenzymes of PDEs (PDE III, IV and V) may be possess both activity; bronchodilatory and anti-inflammatory effects. This results imply that this agents may lead to a re-examination and further subclassification of various types of asthma diseases
